Apellis Pharmaceuticals Inc.
NASDAQ · APLS·Waltham, MA·Mid-cap·Approved
Commercial-stage biotech focused on complement-mediated diseases. Two approved C3 therapies built around pegcetacoplan: SYFOVRE (intravitreal) for geographic atrophy and EMPAVELI (systemic) for paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, and primary immune-complex membranoproliferative glomerulonephritis. Pivotal kidney programs in FSGS and delayed graft function plus a next-generation GA siRNA (APL-3007) extend the C3 franchise.
Decks (2)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Fourth Quarter and Full Year 2025 Financial Results | Earnings | February 24, 2026 | 19 | — |
| 44th Annual J.P. Morgan Healthcare Conference | JPM Healthcare | January 12, 2026 | 29 | — |